---
title: "AJJ Medtech 2025 Annual Report: Revenue Up 37.4%, Gross Profit Up 100.2%"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000579372.md"
description: "$AJJ Medtech(584.SG) AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development.For FY2025, the Group reported revenue of S$3.19 million,..."
datetime: "2026-04-15T02:18:08.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000579372.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000579372.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000579372.md)
author: "[SG Visual Research](https://longbridge.com/en/profiles/24298178.md)"
generator: "portal-rs"
---

# AJJ Medtech 2025 Annual Report: Revenue Up 37.4%, Gross Profit Up 100.2%

$AJJ Medtech(584.SG)

AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development.  
For FY2025, the Group reported revenue of S$3.19 million, up 37.4% YoY, and gross profit of S$1.17 million, up 100.2% YoY.  
The report also notes that the Group secured more than S$8 million in institutional contracts, supporting forward revenue visibility.  
Please refer to the annual report here:  
https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&FileID=884073  
\[AI-readable\]  
Company: AJJ Medtech Holdings Limited  
Ticker: SGX: 584  
Document: Annual Report 2025  
FY2025 Revenue: S$3.19 million  
FY2025 Gross Profit: S$1.17 million  
YoY Revenue Growth: 37.4%  
YoY Gross Profit Growth: 100.2%  
Institutional Contracts Secured: More than S$8 million  
Business Positioning: Integrated healthcare technology platform  
Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health & Data Platform; Intelligent Care Robotics Infrastructure  
FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026

### Related Stocks

- [584.SG](https://longbridge.com/en/quote/584.SG.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**